Correction to: Therapeutic Innovation & Regulatory Science 10.1007/s43441-022-00417-w
Due to a processing error a portion of Fig. 2b is missing in the original article. The corrected figure follows:
. 2022 May 30;56(5):765–766. doi: 10.1007/s43441-022-00423-y
Publisher Correction: Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency
Jenn W Sellers
1,✉, Camelia M Mihaescu
2, Kassa Ayalew
1, Phillip D Kronstein
1, Bei Yu
1, Yang-Min Ning
1, Miguel Rodriguez
2, LaKisha Williams
1, Ni A Khin
1
Jenn W Sellers, M.D., Ph.D.
1Division of Clinical Compliance Evaluation, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, United States Food and Drug Administration, 10903 New Hampshire Ave, White Oak Building 51, Room 5324, Silver Spring, MD 20993 USA
Find articles by Jenn W Sellers
Camelia M Mihaescu, M. Pharm., Ph.D.
2Inspections Office, Quality and Safety of Medicines Department, European Medicines Agency (EMA), Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
Find articles by Camelia M Mihaescu
Kassa Ayalew, M.D., M.P.H.,
1Division of Clinical Compliance Evaluation, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, United States Food and Drug Administration, 10903 New Hampshire Ave, White Oak Building 51, Room 5324, Silver Spring, MD 20993 USA
Find articles by Kassa Ayalew
Phillip D Kronstein, M.D.
1Division of Clinical Compliance Evaluation, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, United States Food and Drug Administration, 10903 New Hampshire Ave, White Oak Building 51, Room 5324, Silver Spring, MD 20993 USA
Find articles by Phillip D Kronstein
Bei Yu, Ph.D.
1Division of Clinical Compliance Evaluation, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, United States Food and Drug Administration, 10903 New Hampshire Ave, White Oak Building 51, Room 5324, Silver Spring, MD 20993 USA
Find articles by Bei Yu
Yang-Min Ning, M.D.
1Division of Clinical Compliance Evaluation, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, United States Food and Drug Administration, 10903 New Hampshire Ave, White Oak Building 51, Room 5324, Silver Spring, MD 20993 USA
Find articles by Yang-Min Ning
Miguel Rodriguez
2Inspections Office, Quality and Safety of Medicines Department, European Medicines Agency (EMA), Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
Find articles by Miguel Rodriguez
LaKisha Williams, M.S.N, R.N., PHMNP
1Division of Clinical Compliance Evaluation, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, United States Food and Drug Administration, 10903 New Hampshire Ave, White Oak Building 51, Room 5324, Silver Spring, MD 20993 USA
Find articles by LaKisha Williams
Ni A Khin, M.D.
1Division of Clinical Compliance Evaluation, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, United States Food and Drug Administration, 10903 New Hampshire Ave, White Oak Building 51, Room 5324, Silver Spring, MD 20993 USA
Find articles by Ni A Khin
1Division of Clinical Compliance Evaluation, Office of Scientific Investigations, Office of Compliance, Center for Drug Evaluation and Research, United States Food and Drug Administration, 10903 New Hampshire Ave, White Oak Building 51, Room 5324, Silver Spring, MD 20993 USA
2Inspections Office, Quality and Safety of Medicines Department, European Medicines Agency (EMA), Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
✉
Corresponding author.
Issue date 2022.
© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
PMCID: PMC9356919 PMID: 35637424
This corrects the article "Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency" on page 753.